Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

Volume: 17, Issue: 3, Pages: 471 - 494
Published: Jan 31, 2014
Abstract
Tumours require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands. Since one or more of the VEGF ligand family is overexpressed in most solid cancers, there was great optimism that inhibition of the VEGF pathway would represent an effective anti-angiogenic therapy for most tumour types. Encouragingly, VEGF...
Paper Details
Title
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Published Date
Jan 31, 2014
Volume
17
Issue
3
Pages
471 - 494
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.